Skip to main content

Table 4 Publications on the role of CDKN2B-AS1 with treatment resistance in cancer

From: Association of cyclin-dependent kinase inhibitor 2B antisense RNA 1 gene expression and rs2383207 variant with breast cancer risk and survival

Cancer site Study type Treatment Putative function Putative mechanism PubMed ID
Osteosarcoma In vitro Cisplatin Chemoresistance Through STAT3 and miR-125a-5p 30777616
Colorectal cancer In vitro 5-Fluorouracil Chemoresistance by regulating ATP-binding cassette subfamily C member 1 through binding Let-7a 30279206
Lung adenocarcinoma In vitro Paclitaxel Chemoresistance Through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2 28402932
Nasopharyngeal carcinoma In vitro Radiation Radioresistance Via functioning as a miR-125a sponge 28402230
In vitro Cisplatin Chemoresistance Via regulating microRNA let-7a 28117929
Multiple myeloma Patients Hematopoietic stem cell transplantation Relapse By modulating p14ARF-MDM2-p53 axis 28150872
Gastric cancer In vitro Cisplatin and 5-fluorouracil Multidrug resistance Decreased the expression of MDR1 and MRP1 27121324
Bladder cancer   Gemcitabine Resistance Through the Wnt signaling pathway 29937935
laryngeal squamous cell cancer   Cisplatin and paclitaxel   CDKN2B-AS1 expression decrease 25257554
Oral squamous cancer   Cisplatin Resistance Via impairment of the drug transporters MRP1 and ABCC2 29176691